4.8 Article

Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours

期刊

NATURE
卷 552, 期 7684, 页码 253-+

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nature24993

关键词

-

资金

  1. UCSD Molecular Biology Cancer Fellowship
  2. US National Institutes of Health [U19AI109976, R01 AI095634]
  3. California Institute for Regenerative Medicine [RB5-07012]
  4. Kimmelman Family Foundation
  5. San Diego Center for Precision Immunotherapy

向作者/读者索取更多资源

Tissue-resident memory CD8(+) T (T-RM) cells are found at common sites of pathogen exposure, where they elicit rapid and robust protective immune responses(1,2). However, the molecular signals that control T-RM cell differentiation and homeostasis are not fully understood. Here we show that mouse T-RM precursor cells represent a unique CD8(+) T cell subset that is distinct from the precursors of circulating memory cell populations at the levels of gene expression and chromatin accessibility. Using computational and pooled in vivo RNA interference screens, we identify the transcription factor Runx3 as a key regulator of T-RM cell differentiation and homeostasis. Runx3 was required to establish T-RM cell populations in diverse tissue environments, and supported the expression of crucial tissue-residency genes while suppressing genes associated with tissue egress and recirculation. Furthermore, we show that human and mouse tumour-infiltrating lymphocytes share a core tissue-residency gene-expression signature with T-RM cells that is associated with Runx3 activity. In a mouse model of adoptive T cell therapy for melanoma, Runx3-deficient CD8(+) tumour-infiltrating lymphocytes failed to accumulate in tumours, resulting in greater rates of tumour growth and mortality. Conversely, overexpression of Runx3 enhanced tumour-specific CD8(+) T cell abundance, delayed tumour growth, and prolonged survival. In addition to establishing Runx3 as a central regulator of T-RM cell differentiation, these results provide insight into the signals that promote T cell residency in non-lymphoid sites, which could be used to enhance vaccine efficacy or adoptive cell therapy treatments that target cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据